Full Press Release Details
Biogen Idec Issues Statement on U.S. Approval of AMPYRA™ (dalfampridine).
BIIB
Biogen Idec Issues Statement on U.S. Approval of AMPYRA™ (dalfampridine)
Key Takeaway: Biogen Idec Issues Statement on U.S. Approval of AMPYRA™ (dalfampridine)